Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in mCRPC
NCT02215161Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Sep 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, San Francisco. Started Sep 2014; status: terminated.
02
Drugs
selinexor
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02215161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215161.